Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2002

01-01-2002 | Case Report

Successful Use of Recombinant Factor VIIa for Hemostasis During Total Knee Replacement in a Severe Hemophiliac with High-Titer Factor VIII Inhibitor

Authors: Marcus E. Carr, Thomas P. Loughran, John A. Cardea, Wade K. Smith, Jan G. Kuhn, Maribeth V. Dottore

Published in: International Journal of Hematology | Issue 1/2002

Login to get access
Metadata
Title
Successful Use of Recombinant Factor VIIa for Hemostasis During Total Knee Replacement in a Severe Hemophiliac with High-Titer Factor VIII Inhibitor
Authors
Marcus E. Carr
Thomas P. Loughran
John A. Cardea
Wade K. Smith
Jan G. Kuhn
Maribeth V. Dottore
Publication date
01-01-2002
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2002
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02981987

Other articles of this Issue 1/2002

International Journal of Hematology 1/2002 Go to the issue

Case Report

Plasma Thrombopoietin in Patients With Cavernous Transformation of the Portal Vein

OriginalPaper

Triple Heterozygosity of a Hemoglobin Variant: Hemoglobin Pyrgos With Other Hemoglobinopathies

OriginalPaper

Molecular Genetics of Type 2 von Willebrand Disease

Editorial

Renaissance of theInternational Journal of Hematology

Letter to the Editor

Successful Unrelated Bone Marrow Transplantation After Arsenic Trioxide Treatment in a Patient With Relapsed Acute Promyelocytic Leukemia

OriginalPaper

Functional Property of von Willebrand Factor Under Flowing Blood
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits